Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences

Core Insights - Kane Biotech Inc. announced new clinical and pre-clinical data showcasing the effectiveness of its FDA-cleared revyve Antimicrobial Wound Gel and revyve Wound Gel Spray in diabetic foot ulcer healing and burn wound infection control [1] Clinical Data: Outperforming the Standard of Care - At the Diabetic Foot Conference 2025, data presented indicated that revyve achieved healing outcomes surpassing the current standard of care for diabetic foot ulcers, with an average percent area reduction (PAR) of 97% in 4 weeks compared to the 40-50% benchmark [2][7] - Complete wound closure was achieved in all cases within 8-12 weeks across a multi-center series [7] - The gel effectively managed bacterial loads, aiding patients with conditions such as Peripheral Arterial Disease and elevated A1c levels [3] Rapid Antimicrobial Efficacy in Burn Care - At the Southern Region Burn Conference, pre-clinical data showed a 99.99% to 99.9999% reduction in burn-associated pathogens within 30 minutes of application, with sustained antibiofilm activity for a minimum of 7 days [4][8] - The product's ability to achieve up to a six-log reduction in microbial load within minutes represents a significant advancement in burn wound management [8] Company Strategy and Future Outlook - These findings are part of Kane's three-pillar strategy aimed at significantly impacting wound care in the United States, emphasizing the potential of revyve's antibiofilm and antimicrobial technology to transform wound healing outcomes [8] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which are major contributors to antibiotic resistance in wounds [11]